Cardiff Oncology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CRDF Nasdaq 2834 www.cardiffoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cardiff Oncology, Inc.

Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital - Jul 15th, 2026 8:54 am
Cardiff Oncology Announces $10 Million Registered Direct Offering - Jul 15th, 2026 6:00 am
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? - Jun 30th, 2026 7:06 am
CRDF: Phase II Update; Survival Advantage Extended - Jun 22nd, 2026 5:41 am
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting - Jun 2nd, 2026 7:06 am
Kazia Therapeutics Appoints James Levine as Chief Financial Officer - Jun 2nd, 2026 5:30 am
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - Jun 1st, 2026 2:01 pm
CRDF: First Quarter 2026 Results - May 22nd, 2026 8:15 am
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC - May 21st, 2026 3:00 pm
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - May 20th, 2026 12:05 pm
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update - May 14th, 2026 2:10 pm
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 28th, 2026 2:01 pm
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity - Apr 27th, 2026 5:00 am
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 - Apr 21st, 2026 8:00 am
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting - Apr 17th, 2026 2:01 pm
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - Apr 9th, 2026 2:01 pm
CRDF: Colorectal Cancer KOL Event - Apr 6th, 2026 4:27 am
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar - Mar 25th, 2026 4:11 pm
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - Mar 20th, 2026 5:00 am
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting - Mar 19th, 2026 5:00 am